Posted on 8/22/17
J&J Wades Into Death Penalty Debate
Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE:JNJ), opposes plans by Florida authorities to use its drug Etomidate in a coming execution, after the state . . .
Posted on 8/22/17
Pfizer: Investors Are Missing The True Impact Of Xtandi
Investment ThesisPfizer (NYSE:PFE) performed satisfactorily in Q2 2017, although investors have not had any meaningful top line growth in for more than a decade. Its operational . . .
Posted on 8/22/17
Better Buy: AbbVie Inc. vs. Pfizer Inc.
There's no question that AbbVie (NYSE:ABBV) shareholders have been happier campers than Pfizer (NYSE:PFE) shareholders in recent years. Whether you compare the two drug stocks over . . .
Posted on 8/22/17
Johnson & Johnson: Bring On The Ambulance Chasers
In May 2015 I was quite despondent. Having a significant portion of my capital in Prospect Capital (PSEC) had my portfolio balance going the way of . . .
Posted on 8/22/17
Champions Oncology Announces Strategic Collaboration with AstraZeneca
Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of . . .
Posted on 8/21/17
CURE Media Group Expands Strategic Alliance Partnership Program with Hope for Stomach Cancer
CRANBURY, N.J.--(BUSINESS WIRE)--CURE Media Group,the nation’s leading consumer digital and print media enterprise focused entirely on patients with cancer, is excited to welcome Hope for Stomach . . .
Posted on 8/21/17
J & J on the Hook for $417M in California Talcum Powder Case
Johnson & Johnson (NYSE:JNJ) is on the losing end of a jury verdict in California in a court case involving a woman who claimed that the . . .
Posted on 8/21/17
Johnson & Johnson: Bring On The Ambulance Chasers
In May 2015 I was quite despondent. Having a significant portion of my capital in Prospect Capital (PSEC) had my portfolio balance going the way of . . .
Posted on 8/21/17
Avista Healthcare Public Acquisition Corp. and Envigo International Holdings To Merge
Avista Healthcare Public Acquisition Corp. (NASDAQ: AHPA), a publicly traded special purpose acquisition company, and Envigo International Holdings, Inc.,
Posted on 8/21/17
3 Top Biotech Stocks Under $10
Cheap and junk don't have to go hand in hand. Sometimes, items that are inexpensive could still have tremendous potential for their values to increase. That . . .
Posted on 8/21/17
Teva Pharmaceutical Industries Limited 2017 Q2 - Results - Earnings Call Slides
The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with their 2017 Q2 earnings call. 129READ FULL ARTICLE HERE
Posted on 8/21/17
Pfizer Inc. 2017 Q2 - Results - Earnings Call Slides
The following slide deck was published by Pfizer Inc. in conjunction with their 2017 Q2 earnings call. 112'READ FULL ARTICLE HERE
Posted on 8/21/17
Snippet Roundup: Transparency For Straumann But A Black Box For Pfizer
Welcome to your weekly roundup of EP Vantage's snippets - short takes on smaller news items.This week, August 14 to 18, 2017, we had thoughts on . . .
Posted on 8/21/17
Pfizer Looks To Sneak In the Market Before Heavy Hitters
On Thursday, Pfizer (PFE) received FDA approval for its drug Besponsa to treat patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). This is a . . .
Posted on 8/21/17
Here's How Much $10,000 Invested in Pfizer in 1977 Is Worth Now
Forty years is a long time. But it's not an unimaginably long time. For many Americans, 40 years is roughly the length of time they will . . .
Posted on 8/21/17
Pfizer's Besponsa Is Yet Another Win for the Biopharma Giant
Pfizer, Inc. (NYSE:PFE) scored another cancer drug victory this past week when the FDA green-lighted Besponsa, a drug that battles back against a rare and deadly . . .
Posted on 8/20/17
Windtree Announces Initiation of Financial Restructuring Program
Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has initiated a financial . . .
Posted on 8/20/17
Champions Oncology Announces Research Collaboration with The Addario Lung Cancer Medical Institute
Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of . . .
Posted on 8/18/17
How Safe Is Johnson & Johnson's Dividend?
Johnson & Johnson (NYSE:JNJ) is one of the best-known companies in America, with most consumers making its over-the-counter products a staple of their medicine cabinets. Yet . . .
Posted on 8/17/17
Health Partners Plans Donates Bicycle Helmets To Individuals with Psychiatric Disabilities
Health Partners Plans delivers bicycle helmets to the Temple University Collaborative on Community Inclusion of Individuals with Psychiatric Disabilities. HPP and collaborative staff (l-r) Alexander Burdzy, . . .
Posted on 8/17/17
L.E.A.F. Pharmaceuticals Establishes its First Subsidiary in Rwanda
L.E.A.F. Pharmaceuticals LLC, a global pharmaceutical company located in the historic area of Valley Forge, Pennsylvania, USA, with a mission to discover, develop and commercialize innovative . . .
Posted on 8/17/17
Stryker’s Spine Division Receives FDA Clearance for Serrato Pedicle Screw
ALLENDALE, N.J.--(BUSINESS WIRE)--Stryker’s Spine division today announced that its Serrato™ Pedicle Screw, intended for use in the non-cervical spine as part of the company’s successful Xia® . . .
Posted on 8/17/17
Vitals Ranks America’s Top Cities for Access to Pediatric Care
LYNDHURST, N.J.--(BUSINESS WIRE)--Many cities in California and Texas have poor patient-reported pediatric care, according to a new 2017 Vitals Access to Pediatricians report. Vitals researched the . . .
Posted on 8/16/17
Why I Love Celgene Corporation
Stocks aren't like children. It's not a problem at all if you don't love each stock in your investment portfolio equally. You can have favorites without . . .
Posted on 8/16/17
Teva: On The Activist Radar
Teva Pharmaceuticals (TEVA) is in the dumps.It’s officially on the activist investor radar. At decade lows, it’s hard not to be tempted by Teva. Generic drug . . .

